EQRx executive chairman Alexis Borisy and CEO Melanie Nallicheri
EQRx's pricing reform model on life support as execs shed PD-L1 plans in US for lung cancer
EQRx placed a substantial bet it could shake up the US healthcare system, promising to bring a swath of drugs to market that was similar …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
